Longevity has become an investment theme and a consumer market at the same time. Both are full of confident forecasts built on thin evidence. Reservoir engineering has a long, painful history with exactly that problem, and a few of its lessons transfer surprisingly well.
A good history match is not a good forecast
In reservoir simulation, many different models can reproduce the same production history and still forecast very different futures. Engineers call this non-uniqueness. Medicine has the same trap in surrogate endpoints: an intervention can move a biomarker convincingly without changing the outcome that matters, which is how long and how well people live. A changed number is a match to history; it is not yet a forecast.
Grade the evidence before you price it
Before valuing a field, we classify how well each number is known: measured, inferred from analogues, or assumed. Longevity claims deserve the same treatment. Randomised trials on hard outcomes sit at the top; mechanistic arguments and short-term biomarker studies sit much lower. An investment case built on the bottom tier should be priced as exploration, not as a producing asset.
Value of information
The most useful question in any uncertain decision is what the next piece of information is worth. For a health system or an investor, funding well-designed trials and registries is often worth more than funding the next clinic, because it tells you which clinics are worth building.
The industry that learns to say "we don't know yet, and here is how we will find out" will earn the trust the rest of the market is spending.
This is the lens I bring to health and regenerative-medicine projects in the MEA region: rigorous about what the evidence supports, explicit about what it does not, and structured so that capital follows proof.